Deep vein thrombosis treated with streptokinase or heparin. A randomized study

Area of Science:

• Vascular Medicine
• Pharmacology
• Radiology

Background:

• Deep vein thrombosis (DVT) is a significant vascular condition.
• Effective thrombolytic therapy is crucial for managing DVT.
• Comparing streptokinase and heparin for DVT treatment requires further investigation.

Purpose of the Study:

• To compare the efficacy of streptokinase and heparin in treating deep vein thrombosis.
• To assess thrombolytic effects at different time points (3 and 10 days).
• To investigate potential differences in treatment outcomes based on patient demographics (sex) and symptom duration.

Main Methods:

• A randomized trial involving 50 patients with DVT (duration < 2 weeks).
• Patients received either streptokinase or heparin therapy.
• Venography was performed at baseline, 3 days, and 10 days.
• Radiologists assessed thrombus lysis using a standardized scoring system.

Main Results:

• Streptokinase showed significantly greater thrombus lysis than heparin after 3 days.
• This significant difference was not observed after 10 days of treatment.
• Male patients with symptoms for ≤3 days had better lysis with streptokinase (P < .01).
• Female patients showed no significant difference in lysis between the two therapies, irrespective of symptom duration.

Conclusions:

• Streptokinase offers a potential early advantage in DVT lysis, particularly in specific male patient subgroups.
• Heparin may be a comparable alternative for DVT treatment over a 10-day period, especially for female patients.
• Further research is needed to optimize thrombolytic strategies based on patient characteristics and treatment duration.